Trial Profile

A Phase 1b, Open-label, Pilot Study of CLN-978 Administered Subcutaneously for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jan 2026 According to a Cullinan Therapeutics media release, the 10- and 20-microgram dose cohorts in this trial are complete, and patients are currently being enrolled in the 30-microgram dose cohort. In Q2 2026, the Company plans to share initial data from Part A (single target dose escalation).
06 Nov 2025 According to a Cullinan Therapeutics media release, company plans to share initial data from this study in 1H 2026.
27 Feb 2025 According to Cullinan Therapeutics media release, the company announced that initial clinical data from this global Phase 1 study of CLN-978 is expected in Q4 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com